Journal
ONCOGENE
Volume 19, Issue 13, Pages 1623-1634Publisher
STOCKTON PRESS
DOI: 10.1038/sj.onc.1203473
Keywords
PML; nuclear bodies; APL; RING; RNA transport
Funding
- NCI NIH HHS [R01 CA80728] Funding Source: Medline
Ask authors/readers for more resources
The majority of the promyelocytic leukemia (PML) protein is present in nuclear bodies which are altered in several pathogenic conditions including acute promyelocytic leukemia. PML nuclear bodies are found in nearly all cells yet their function remains unknown. Here, we demonstrate that PML and the eukaryotic initiation factor 4E (eIF-4E) co-localize and co-immunopurify. eIF-4E is involved in nucleocytoplasmic transport of specific mRNAs including cyclin D1, eIF-4E overexpression leads to increased cyclin D1 protein levels;,whereas, overexpression of PML leads to decreased cyclin D1 le,els. Neither PML nor eIF-4E cause significant changes in cyclin D1 mRNA levels. The association with eIF-4E led us to investigate if PML could alter mRNA distribution as a possible post-transcriptional mechanism for suppressing cyclin D1 production. We show that overexpression of PML results in nuclear retention of cyclin D1 mRNA and that intact PR-IL nuclear bodies are required. Addition of eIF-4E overcomes PML induced retention and alters the morphology of PML bodies suggesting a mechanism by which eIF-4E can modulate PML function. These results raise the possibility that PML nuclear bodies may participate in the regulation of nucleocytoplasmic transport of specific mRNAs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available